We are live on ! Find out more
SCM

Stonepine Capital Management Portfolio holdings

AUM $250M
1-Year Est. Return 77.6%
This Fund
S&P 500
This Quarter Est. Return
-3.86%
1 Year Est. Return
+77.6%
3 Year Est. Return
+198.76%
5 Year Est. Return
+226.15%
10 Year Est. Return
+1,976.54%
AUM
$103M
AUM Growth
-$21.1M
Cap. Flow
-$8.51M
Cap. Flow %
-8.28%
Top 10 Hldgs %
58.07%
Holding
75
New
23
Increased
18
Reduced
24
Closed
9

Top Buys

Rank Stock Value
1
SRZN icon
Surrozen
SRZN
+$1.73M
2
ANIP icon
ANI Pharmaceuticals
ANIP
+$1.65M
3
ENTA icon
Enanta Pharmaceuticals
ENTA
+$1.6M
4
EDSA icon
Edesa Biotech
EDSA
+$1.48M
5
OPTN
OptiNose
OPTN
+$1.26M

Top Sells

Rank Stock Value
1
ADMA icon
ADMA Biologics
ADMA
+$7.45M
2
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$2.87M
3
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$2.68M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$2.3M
5
EOLS icon
Evolus
EOLS
+$1.7M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACAD icon
51
Acadia Pharmaceuticals
ACAD
$4.39B
$186K 0.18%
93,393
-126,607
-58% -$2.3M
CRBP icon
52
Corbus Pharmaceuticals
CRBP
$165M
$186K 0.18%
+35,000
New +$309K
VNDA icon
53
Vanda Pharmaceuticals
VNDA
$315M
$161K 0.16%
35,148
+10,148
+41% +$47.3K
PYPD icon
54
PolyPid
PYPD
$83.6M
$149K 0.15%
54,975
-48,693
-47% -$145K
AMRN
55
Amarin Corp
AMRN
$297M
$105K 0.1%
32,581
+26,868
+470% +$284K
ELAN icon
56
Elanco Animal Health
ELAN
$12.8B
$105K 0.1%
+10,000
New +$113K
ZNTL icon
57
Zentalis Pharmaceuticals
ZNTL
$331M
$95.4K 0.09%
+60,000
New +$129K
WHWK
58
Whitehawk Therapeutics
WHWK
$196M
$83.1K 0.08%
+46,698
New +$122K
SVRA icon
59
Savara
SVRA
$1.09B
$80.5K 0.08%
+29,079
New +$80.3K
IOVA icon
60
Iovance Biotherapeutics
IOVA
$1.93B
$66.6K 0.06%
+20,000
New +$103K
THTX
61
DELISTED
Theratechnologies
THTX
$36.2K 0.04%
+25,825
New +$43.1K
ADMA icon
62
ADMA Biologics
ADMA
$2.03B
$24.3K 0.02%
810,000
-431,032
-35% -$7.45M
EBS icon
63
Emergent Biosolutions
EBS
$382M
$24.3K 0.02%
+5,000
New +$41.4K
NKTX icon
64
Nkarta
NKTX
$154M
$18.4K 0.02%
+10,000
New +$20.5K
APRE icon
65
Aprea Therapeutics
APRE
$7.4M
$14.4K 0.01%
102,242
-46,979
-31% -$147K
ESPR
66
DELISTED
Esperion Therapeutics
ESPR
$14.4K 0.01%
+10,000
New +$18.4K
ABVX
67
Abivax
ABVX
$10.9B
– –
-15,000
Closed -$110K
ALLR
68
Allarity Therapeutics
ALLR
$20.2M
– –
-67,289
Closed -$78.7K
ANTX icon
69
AN2 Therapeutics
ANTX
$201M
– –
-196,732
Closed -$271K
ELEV
70
DELISTED
Elevation Oncology
ELEV
– –
-200,000
Closed -$113K
IRWD icon
71
Ironwood Pharmaceuticals
IRWD
$728M
– –
-648,785
Closed -$2.87M
JAZZ icon
72
Jazz Pharmaceuticals
JAZZ
$15.8B
– –
-10,000
Closed -$1.23M
TSVT
73
DELISTED
2seventy bio
TSVT
– –
-300,000
Closed -$882K
RVNC
74
DELISTED
Revance Therapeutics, Inc.
RVNC
– –
-23,264
Closed -$70.7K
1 2
3

Similar funds

ER
EVR Research Richmond, Virginia $250M AUM 41.5% 1-Year Est. Return
FDDB
Fidelity D&D Bancorp Dunmore, Pennsylvania $249M AUM 18.9% 1-Year Est. Return
VM
VPR Management Houston, Texas $250M AUM 34.13% 1-Year Est. Return
SCM
Step Capital Management Singapore $249M AUM
CWM
Chicago Wealth Management Chicago, Illinois $251M AUM 45.31% 1-Year Est. Return
EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
TAM
Tabor Asset Management New York $249M AUM 48.59% 1-Year Est. Return

Stonepine Capital Management's Q1 2025 Portfolio in Review

As of Q1 2025, Stonepine Capital Management held 75 positions worth $103M, down 17% from $124M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Stonepine Capital Management withdrew a net $8.51M in Q1 2025, closing 9 positions and reducing 24 holdings. Its most notable exit was Ironwood Pharmaceuticals, an estimated $2.87M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

Against the trend, Stonepine Capital Management opened a new position in Edesa Biotech worth $1.68M.

  • Stonepine Capital Management's largest Q1 2025 buy was Edesa Biotech: 687,500 shares worth $1.68M.
  • Stonepine Capital Management added most to Surrozen in Q1 2025, an estimated $1.73M increase.
  • Stonepine Capital Management's biggest Q1 2025 reduction was ADMA Biologics, cutting an estimated $7.45M.
  • Stonepine Capital Management fully exited Ironwood Pharmaceuticals in Q1 2025, selling an estimated $2.87M.
  • Stonepine Capital Management's ten largest holdings make up 58% of its $103M portfolio in Q1 2025.
  • Stonepine Capital Management opened 23 new positions and closed 9 in Q1 2025.
  • Stonepine Capital Management's portfolio value fell 17% quarter-over-quarter to $103M.

Based on Stonepine Capital Management's 13F filing for Q1 2025, filed 14 May 2025.